U.S. Markets closed

Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

ALLISON GATLIN
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

Leading biotech Amgen could expand the market for Repatha by 4.5 million patients with high cholesterol if the PCSK9 inhibitor proves its mettle in a new study, an analyst said Friday.